Cyclophosphamide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00531 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 77 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | myeloid leukemia | KG + DL |
| 2 | ganglioneuroblastoma (disease) | KG + DL |
| 3 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 4 | retroperitoneal neoplasm | KG + DL |
| 5 | lymph node cancer | KG + DL |
| 6 | lymphoma, non-Hodgkin, familial | KG + DL |
| 7 | acute lymphoblastic leukemia (disease) | KG + DL |
| 8 | myelodysplastic syndrome | KG + DL |
| 9 | unclassified myelodysplastic syndrome | KG + DL |
| 10 | refractory cytopenia of childhood | KG + DL |
| 11 | B-cell neoplasm | KG + DL |
| 12 | aregenerative anemia | KG + DL |
| 13 | colon adenocarcinoma | KG + DL |
| 14 | mantle cell lymphoma | KG + DL |
| 15 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 16 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 17 | follicular lymphoma | KG + DL |
| 18 | acute lymphoblastic/lymphocytic leukemia | KG + DL |
| 19 | primary cutaneous B-cell lymphoma | KG + DL |
| 20 | Sezary syndrome | KG + DL |
| 21 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 22 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 23 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 24 | indolent plasma cell myeloma | KG + DL |
| 25 | primary cutaneous T-cell non-Hodgkin lymphoma | KG + DL |
| 26 | interdigitating dendritic cell sarcoma | KG + DL |
| 27 | small intestinal Burkitt lymphoma | KG + DL |
| 28 | neoplasm of mature B-cells | KG + DL |
| 29 | malignant phyllodes tumor | KG + DL |
| 30 | subcutaneous panniculitis-like T-cell lymphoma | KG + DL |
| 31 | small intestinal mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 32 | lymphoid neoplasm | KG + DL |
| 33 | breast mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 34 | primary organ-specific lymphoma | KG + DL |
| 35 | reticulum cell sarcoma | KG + DL |
| 36 | tonsillar lymphoma | KG + DL |
| 37 | thyroid gland mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 38 | follicular lymphoma, susceptibility to, 1 | KG + DL |
| 39 | indolent primary cutaneous T-cell lymphoma | KG + DL |
| 40 | Ewing sarcoma | KG + DL |
| 41 | precursor lymphoblastic lymphoma/leukemia | KG + DL |
| 42 | malignant breast phyllodes tumor | KG + DL |
| 43 | MALT lymphoma | KG + DL |
| 44 | acute lymphoblastic leukemia | KG + DL |
| 45 | B-cell prolymphocytic leukemia | KG + DL |
| 46 | plasma cell neoplasm | KG + DL |
| 47 | tetra-amelia | KG + DL |
| 48 | heavy chain disease | KG + DL |
| 49 | leukemia, lymphocytic, susceptibility to | KG + DL |
| 50 | Richter syndrome | KG + DL |
(Showing top 50 of 77 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.